Trade Caribou Biosciences, Inc. - CRBU CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 5.11 |
| Open* | 5.08 |
| 1-Year Change* | -44.96% |
| Day's Range* | 5 - 5.3 |
| 52 wk Range | 4.12-13.19 |
| Average Volume (10 days) | 515.24K |
| Average Volume (3 months) | 9.90M |
| Market Cap | 325.50M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 61.30M |
| Revenue | 13.85M |
| EPS | -1.63 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2023 | 5.30 | 0.19 | 3.72% | 5.11 | 5.30 | 4.98 |
| Mar 30, 2023 | 5.11 | -0.04 | -0.78% | 5.15 | 5.25 | 4.90 |
| Mar 29, 2023 | 5.13 | 0.34 | 7.10% | 4.79 | 5.18 | 4.67 |
| Mar 28, 2023 | 4.69 | 0.03 | 0.64% | 4.66 | 4.87 | 4.54 |
| Mar 27, 2023 | 4.68 | 0.06 | 1.30% | 4.62 | 4.78 | 4.49 |
| Mar 24, 2023 | 4.62 | 0.38 | 8.96% | 4.24 | 4.69 | 4.18 |
| Mar 23, 2023 | 4.26 | -0.11 | -2.52% | 4.37 | 4.43 | 4.10 |
| Mar 22, 2023 | 4.32 | -0.43 | -9.05% | 4.75 | 4.75 | 4.31 |
| Mar 21, 2023 | 4.79 | -0.08 | -1.64% | 4.87 | 4.90 | 4.74 |
| Mar 20, 2023 | 4.85 | -0.04 | -0.82% | 4.89 | 4.91 | 4.69 |
| Mar 17, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.02 | 4.80 |
| Mar 16, 2023 | 5.02 | -0.07 | -1.38% | 5.09 | 5.15 | 4.91 |
| Mar 15, 2023 | 5.15 | 0.10 | 1.98% | 5.05 | 5.25 | 5.02 |
| Mar 14, 2023 | 5.18 | -0.25 | -4.60% | 5.43 | 5.51 | 5.10 |
| Mar 13, 2023 | 5.30 | 0.25 | 4.95% | 5.05 | 5.34 | 5.02 |
| Mar 10, 2023 | 5.14 | -0.29 | -5.34% | 5.43 | 5.48 | 4.93 |
| Mar 9, 2023 | 5.48 | -0.35 | -6.00% | 5.83 | 5.85 | 5.33 |
| Mar 8, 2023 | 5.85 | 0.02 | 0.34% | 5.83 | 5.92 | 5.75 |
| Mar 7, 2023 | 5.86 | 0.03 | 0.51% | 5.83 | 6.04 | 5.70 |
| Mar 6, 2023 | 5.77 | -0.32 | -5.25% | 6.09 | 6.09 | 5.54 |
Caribou Biosciences, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Total revenue | 13.851 | 9.598 | 12.361 | 5.788 |
| Revenue | 13.851 | 9.598 | 12.361 | 5.788 |
| Total Operating Expense | 120.25 | 74.993 | 48.485 | 40.093 |
| Selling/General/Admin. Expenses, Total | 38.02 | 24.322 | 14.06 | 16.458 |
| Research & Development | 82.23 | 52.255 | 34.425 | 23.635 |
| Operating Income | -106.399 | -65.395 | -36.124 | -34.305 |
| Interest Income (Expense), Net Non-Operating | -0.133 | 0.14 | -0.517 | 3.337 |
| Other, Net | 7.181 | -1.347 | 0.514 | 0 |
| Net Income Before Taxes | -99.351 | -66.602 | -36.127 | -30.968 |
| Net Income After Taxes | -99.421 | -66.923 | -34.308 | -23.431 |
| Net Income Before Extra. Items | -99.421 | -66.923 | -34.308 | -23.431 |
| Net Income | -99.421 | -66.923 | -34.308 | -23.431 |
| Income Available to Common Excl. Extra. Items | -99.421 | -66.923 | -34.308 | -23.431 |
| Income Available to Common Incl. Extra. Items | -99.421 | -66.923 | -34.308 | -23.431 |
| Diluted Net Income | -99.421 | -66.923 | -34.308 | -23.431 |
| Diluted Weighted Average Shares | 60.8011 | 60.2632 | 56.7092 | 56.7092 |
| Diluted EPS Excluding Extraordinary Items | -1.63518 | -1.11051 | -0.60498 | -0.41318 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.63518 | -1.1276 | -0.60498 | -0.41318 |
| Unusual Expense (Income) | 0 | -1.584 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Total revenue | 3.692 | 3.303 | 4.192 | 2.664 | 2.559 |
| Revenue | 3.692 | 3.303 | 4.192 | 2.664 | 2.559 |
| Total Operating Expense | 34.27 | 29.84 | 32.623 | 23.517 | 22.964 |
| Selling/General/Admin. Expenses, Total | 8.534 | 9.849 | 10.044 | 9.593 | 7.853 |
| Research & Development | 25.736 | 19.991 | 22.579 | 13.924 | 15.111 |
| Operating Income | -30.578 | -26.537 | -28.431 | -20.853 | -20.405 |
| Interest Income (Expense), Net Non-Operating | -0.06 | 0.031 | -0.016 | 0.163 | 0.076 |
| Other, Net | 3.719 | -0.141 | 1.75 | 1.602 | 2.171 |
| Net Income Before Taxes | -26.919 | -26.647 | -26.697 | -19.088 | -18.158 |
| Net Income After Taxes | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Net Income Before Extra. Items | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Net Income | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Income Available to Common Excl. Extra. Items | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Income Available to Common Incl. Extra. Items | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Diluted Net Income | -26.989 | -26.647 | -26.697 | -19.088 | -18.479 |
| Diluted Weighted Average Shares | 61.01 | 60.8869 | 60.7577 | 60.5462 | 60.2632 |
| Diluted EPS Excluding Extraordinary Items | -0.44237 | -0.43765 | -0.4394 | -0.31526 | -0.30664 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.44237 | -0.43765 | -0.4394 | -0.31526 | -0.30664 |
| Unusual Expense (Income) | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Total Current Assets | 391.192 | 24.306 | 57.008 |
| Cash and Short Term Investments | 375.832 | 15.953 | 49.471 |
| Cash & Equivalents | 240.42 | 15.953 | 41.07 |
| Short Term Investments | 135.412 | 0 | 8.401 |
| Total Receivables, Net | 8.124 | 5.16 | 3.982 |
| Accounts Receivable - Trade, Net | 2.641 | 1.478 | 0.841 |
| Prepaid Expenses | 6.565 | 2.433 | 3.182 |
| Other Current Assets, Total | 0.671 | 0.76 | 0.373 |
| Total Assets | 442.356 | 36.046 | 61.933 |
| Property/Plant/Equipment, Total - Net | 4.887 | 3.502 | 4.332 |
| Property/Plant/Equipment, Total - Gross | 8.964 | 6.598 | 6.59 |
| Accumulated Depreciation, Total | -4.077 | -3.096 | -2.258 |
| Long Term Investments | 45.302 | 7.626 | 0 |
| Other Long Term Assets, Total | 0.975 | 0.612 | 0.593 |
| Total Current Liabilities | 25.829 | 12.389 | 10.078 |
| Accounts Payable | 3.99 | 2.601 | 2.537 |
| Accrued Expenses | 12.089 | 8.151 | 5.653 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.654 | 0 |
| Other Current Liabilities, Total | 9.75 | 0.983 | 1.888 |
| Total Liabilities | 54.531 | 18.16 | 13.147 |
| Total Long Term Debt | 0 | 0.924 | 0 |
| Long Term Debt | 0 | 0.924 | 0 |
| Deferred Income Tax | 0.476 | 0.155 | 0.65 |
| Other Liabilities, Total | 28.226 | 4.692 | 2.419 |
| Total Equity | 387.825 | 17.886 | 48.786 |
| Preferred Stock - Non Redeemable, Net | 0 | 41.323 | 41.323 |
| Common Stock | 0.006 | 0.001 | 0.001 |
| Additional Paid-In Capital | 485.748 | 7.433 | 4.025 |
| Retained Earnings (Accumulated Deficit) | -97.794 | -30.871 | 3.437 |
| Total Liabilities & Shareholders’ Equity | 442.356 | 36.046 | 61.933 |
| Total Common Shares Outstanding | 60.2632 | 56.7092 | 56.7092 |
| Other Equity, Total | -0.135 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 368.01 | 391.192 | 449.047 | 142.967 | 155.925 |
| Cash and Short Term Investments | 353.731 | 375.832 | 435.31 | 129.524 | 145.924 |
| Cash & Equivalents | 147.63 | 240.42 | 435.31 | 129.524 | 145.924 |
| Total Receivables, Net | 6.037 | 8.124 | 7.785 | 8.407 | 5.825 |
| Accounts Receivable - Trade, Net | 1.868 | 2.641 | 2.431 | 0.832 | 1.049 |
| Prepaid Expenses | 7.276 | 6.565 | 5.189 | 3.759 | 3.096 |
| Other Current Assets, Total | 0.966 | 0.671 | 0.763 | 1.277 | 1.08 |
| Total Assets | 445.997 | 442.356 | 461.96 | 158.397 | 167.965 |
| Property/Plant/Equipment, Total - Net | 31.765 | 4.887 | 4.477 | 4.408 | 3.38 |
| Property/Plant/Equipment, Total - Gross | 36.15 | 8.964 | 8.282 | 7.952 | 6.695 |
| Accumulated Depreciation, Total | -4.385 | -4.077 | -3.805 | -3.544 | -3.315 |
| Long Term Investments | 44.758 | 45.302 | 7.626 | 7.626 | 7.626 |
| Other Long Term Assets, Total | 1.464 | 0.975 | 0.81 | 3.396 | 1.034 |
| Total Current Liabilities | 26.667 | 25.829 | 26.158 | 26.007 | 22.21 |
| Accounts Payable | 1.814 | 3.99 | 3.482 | 4.029 | 3.117 |
| Accrued Expenses | 11.215 | 12.089 | 12.288 | 11.034 | 10.929 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0.655 | |
| Other Current Liabilities, Total | 13.638 | 9.75 | 10.388 | 10.944 | 7.509 |
| Total Liabilities | 74.2 | 54.531 | 57.559 | 55.938 | 53.504 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0.926 |
| Long Term Debt | 0 | 0 | 0 | 0.926 | |
| Deferred Income Tax | 0.476 | 0.476 | 0.155 | 0.155 | 0.155 |
| Other Liabilities, Total | 47.057 | 28.226 | 31.246 | 29.776 | 30.213 |
| Total Equity | 371.797 | 387.825 | 404.401 | 102.459 | 114.461 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 150.15 | 150.15 |
| Common Stock | 0.006 | 0.006 | 0.006 | 0.001 | 0.001 |
| Additional Paid-In Capital | 489.762 | 485.748 | 483.71 | 10.649 | 8.34 |
| Retained Earnings (Accumulated Deficit) | -116.882 | -97.794 | -79.315 | -58.341 | -44.03 |
| Total Liabilities & Shareholders’ Equity | 445.997 | 442.356 | 461.96 | 158.397 | 167.965 |
| Total Common Shares Outstanding | 60.6896 | 60.2632 | 60.0213 | 59.9708 | 56.7092 |
| Short Term Investments | 206.101 | 135.412 | |||
| Other Equity, Total | -1.089 | -0.135 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Net income/Starting Line | -99.421 | -66.923 | -34.308 | -23.431 |
| Cash From Operating Activities | -90.966 | -32.519 | -33.215 | -32.006 |
| Cash From Operating Activities | 1.622 | 0.984 | 0.9 | 0.751 |
| Non-Cash Items | 11.037 | 4.353 | 0.016 | -1.059 |
| Cash Taxes Paid | 0 | 0.011 | 0.021 | 1.809 |
| Changes in Working Capital | -4.204 | 29.067 | 0.177 | -8.267 |
| Cash From Investing Activities | -93.249 | -176.397 | 6.363 | 27.233 |
| Capital Expenditures | -6.454 | -2.121 | -0.317 | -0.884 |
| Other Investing Cash Flow Items, Total | -86.795 | -174.276 | 6.68 | 28.117 |
| Cash From Financing Activities | 2.133 | 433.429 | 1.735 | 0.172 |
| Issuance (Retirement) of Stock, Net | 2.133 | 432.398 | 1.848 | 0.217 |
| Issuance (Retirement) of Debt, Net | 0 | 1.031 | -0.113 | -0.045 |
| Net Change in Cash | -182.082 | 224.513 | -25.117 | -4.601 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -99.421 | -72.432 | -45.785 | -19.088 | -66.923 |
| Cash From Operating Activities | -90.966 | -65.922 | -43.546 | -21.673 | -32.519 |
| Cash From Operating Activities | 1.622 | 1.116 | 0.666 | 0.308 | 0.984 |
| Non-Cash Items | 11.037 | 9.47 | 4.942 | 2.215 | 4.353 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0.011 |
| Cash Interest Paid | 0 | ||||
| Changes in Working Capital | -4.204 | -4.076 | -3.369 | -5.108 | 29.067 |
| Cash From Investing Activities | -93.249 | -94.419 | -86.08 | -72.107 | -176.397 |
| Capital Expenditures | -6.454 | -4.697 | -3.343 | -0.723 | -2.121 |
| Other Investing Cash Flow Items, Total | -86.795 | -89.722 | -82.737 | -71.384 | -174.276 |
| Cash From Financing Activities | 2.133 | 2.006 | 1.352 | 0.99 | 433.429 |
| Issuance (Retirement) of Stock, Net | 2.133 | 2.006 | 1.352 | 0.99 | 432.398 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | 1.031 |
| Net Change in Cash | -182.082 | -158.335 | -128.274 | -92.79 | 224.513 |
| Financing Cash Flow Items | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| PFM Health Sciences, LP | Hedge Fund | 7.2754 | 4459783 | -1540217 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.6832 | 4096777 | 277588 | 2022-12-31 | LOW |
| Haurwitz (Rachel E. Ph.D.) | Individual Investor | 5.5129 | 3379395 | 10000 | 2023-03-20 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.2184 | 3198893 | 803423 | 2022-12-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 4.7025 | 2882600 | -290000 | 2022-12-31 | HIGH |
| Rokos Capital Management LLP | Hedge Fund | 4.4831 | 2748139 | 840630 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1939 | 2570827 | 26789 | 2022-12-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.1662 | 2553878 | -737020 | 2022-12-31 | LOW |
| Elmwood Wealth Management, INC. | Investment Advisor | 3.8569 | 2364240 | 0 | 2022-12-31 | LOW |
| EIDP Inc | Corporation | 3.3573 | 2058000 | -1093311 | 2022-05-31 | MED |
| BofA Global Research (US) | Research Firm | 3.008 | 1843902 | 1668395 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.3541 | 1443046 | -547 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.982 | 1214933 | 30615 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6819 | 1030987 | 45617 | 2022-12-31 | LOW |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 1.4575 | 893424 | -138016 | 2022-12-31 | LOW |
| Fidelity International | Investment Advisor | 1.404 | 860666 | 0 | 2022-12-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3944 | 854738 | 55247 | 2022-12-31 | HIGH |
| Maverick Capital, Ltd. | Hedge Fund | 1.0645 | 652542 | 0 | 2022-12-31 | MED |
| Tekla Capital Management LLC | Investment Advisor | 0.9252 | 567147 | 0 | 2022-12-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.9215 | 564855 | -1059 | 2022-12-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Caribou Biosciences, Inc. Company profile
About Caribou Biosciences Inc
Caribou Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company uses clustered regularly interspaced short palindromic repeats (CRISPR) genome editing to discover and develop immune cell-based therapeutics for cancer. It is focused on developing a pipeline of genome-edited off-the-shelf CAR-T cell and natural killer (NK) cell therapies for a range of tumor types. It also offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics and industrial biotechnology. The Company's pipeline includes CB-010, CB-011, CB-012 and CB-020.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Caribou Biosciences Inc revenues totaled $7M. Net loss totaled to $48.4M.
| Industry: | Biotechnology & Medical Research (NEC) |
2929 7Th Street, Ste 120
BERKELEY
CALIFORNIA 94710
US
Income Statement
- Annual
- Quarterly
News
PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com